Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.52 |
| ▸ | NAAA | Q02083 | 4/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219825 | 0.84 | LMNA (0.46) | GPR84ALOX5ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21754889 | 0.80 | GPR84 (0.67) | GPR84NAAAALOX5USP2TSHR | |
| SCHEMBL23249774 | 0.76 | NPC1 (0.57) | GPR84ALDH1A1LMNASMN1; SMN2USP2 | |
| SCHEMBL18123748 | 0.74 | CTSL (0.46) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL14812810 | 0.73 | NAAA (0.66) | GPR84NAAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14812246 | 0.73 | NAAA (0.66) | GPR84NAAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14816297 | 0.73 | NAAA (0.66) | GPR84NAAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31506926 | 0.72 | KDM4E (0.54) | GPR84LMNA | |
| SCHEMBL10145717 | 0.71 | ALDH1A1 (0.52) | GPR84NAAAALOX5ALDH1A1LMNA | |
| SCHEMBL16596188 | 0.71 | HDAC1 (0.71) | NAAAALOX5USP2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045522-B2 | Nucleic acid amplification using a reversibly modified oligonucleotide | Bi, Wanli (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130122507-A1 | Nucleic Acid Amplification Using A Reversibly Modified Oligonucleotide | SUZHOU NUHIGH BIOTECHNOLOGIES CO., LTD (CN) | 2013-05-16 | — | — | US | disclosed |
| US-8334099-B2 | Nucleic acid amplification using a reversibly modified oligonucleotide | BI WANLI (US) | 2012-12-18 | — | — | US | disclosed |
| WO-2010021897-A1 | NUCLEOSIDIC PHOSPHORAMIDITE CRYSTALLINE MATERIAL AND A PROCESS FOR PURIFYING THE SAME | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100021970-A1 | Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide | BI WANLI | 2010-01-28 | — | — | US | disclosed |
| US-7057062-B2 | Process for manufacturing purified phosphorodiamidite | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1492800-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | IONIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087130-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | PHOSPHO1, PNP, OSGEP | GPR84 4190/4885NAAA 1537/4885ALOX5 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.